Product Search
We provide safer and differentiated healthcare products to customers
by combining medical technologies.
PRODUCT
Rabeton Tab. 20mg
Print
product information
Rabeton Tab. 20mg
| Classification | Ethical the Counter(ETC) |
|---|---|
| Major Ingredients | Rabeprazole sodium |
| Efficacy/Effectiveness | Gastric ulcer, duodenal ulcer, erosive or ulcerative gastroesophageal reflux disease, symptom relief |
| Appearance | Light yellow circular film coating |
product information
Information
1) Components and content
- One tablet -
Rabeprazole sodium -------- 20.0 mg
2) Usage and dosage Gastric ulcer, duodenal ulcer:
Normally, 10 mg of rabeprazole sodium is orally administered to an adult once a day. Depending on the symptoms, 20 milligrams can be orally administered once a day. Usually, up to 8 weeks for gastric ulcers, and 6 weeks for duodenal ulcers
3) Storage
Closed container, storage at room temperature (1 ~ 30 ℃)
4) Packing unit
Our Packing Unit
5) Period
36 months from date of manufacture
- One tablet -
Rabeprazole sodium -------- 20.0 mg
2) Usage and dosage Gastric ulcer, duodenal ulcer:
Normally, 10 mg of rabeprazole sodium is orally administered to an adult once a day. Depending on the symptoms, 20 milligrams can be orally administered once a day. Usually, up to 8 weeks for gastric ulcers, and 6 weeks for duodenal ulcers
3) Storage
Closed container, storage at room temperature (1 ~ 30 ℃)
4) Packing unit
Our Packing Unit
5) Period
36 months from date of manufacture
Details
[Precautions for use]
1. Do not administer to the following patients
Patients who are hypersensitive to the components of this drug or benzimidazole
2. The following patients should be treated with caution
1) Patients with hepatic impairment (mental nervous system adverse reactions of hepatic encephalopathy were reported in patients with liver cirrhosis.)
2) Elderly (refer to the administration section for the elderly)
1. Do not administer to the following patients
Patients who are hypersensitive to the components of this drug or benzimidazole
2. The following patients should be treated with caution
1) Patients with hepatic impairment (mental nervous system adverse reactions of hepatic encephalopathy were reported in patients with liver cirrhosis.)
2) Elderly (refer to the administration section for the elderly)